Organon & Co. (OGN) Stock Price & Analysis

Organon & Co. (OGN) rose 0.07% to USD 13.4 as of June 10, 2026 at 00:29 UTC, according to Nexqual real-time market data.

OGN last closed at USD 13.39; the session ranged USD 13.38–13.45 on volume of 1,721,738 shares. Market capitalization is $3.52B, with a 52-week range of USD 5.69–13.48 (NYQ). Source: Nexqual, June 10, 2026 at 00:29 UTC.

Key Statistics (as of June 10, 2026 at 00:29 UTC)

Technical Analysis (OGN)

Nexqual's technical model rates OGN "BUY" based on 5 bullish and 1 bearish signals across 124 daily candles, as of June 10, 2026 at 00:29 UTC.

Analyst Ratings (OGN)

Wall Street analysts rate OGN "None" based on 4 analysts, with a mean price target of USD 11.25 (range USD 8–14), per Nexqual as of June 10, 2026 at 00:29 UTC.

Earnings (OGN)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 00:29 UTC.

Financials & Fundamentals (OGN)

Source: Nexqual, June 10, 2026 at 00:29 UTC.

Financial Health Score (OGN)

Nexqual rates Organon & Co.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 00:29 UTC.

Ownership (OGN)

Source: Nexqual, June 10, 2026 at 00:29 UTC.

Leadership (OGN)

Organon & Co. is led by Joseph T. Morrissey (age 60), Chief Executive Officer, per Nexqual as of June 10, 2026 at 00:29 UTC.

Major Backers & Investors (OGN)

Notable institutional backers of Organon & Co. include LSV Asset Management, Millennium Management, Kahn Brothers Group Inc., according to Nexqual as of June 10, 2026 at 00:29 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 00:29 UTC.

From Organon & Co.'s Latest SEC 10-K Filing (filed 2026-02-24)

Key Strengths & Strategy (as disclosed to the SEC)

• We operate on a global scale through a global network that enables us to distribute products to patients in more than 140 countries and territories, with approximately 74% of our 2025 revenues, or $4.6 billion, generated outside the United States. -4- Table of Contents Women's Health Portfolio In 2025, our women's health portfolio accounted for $1.8 billion, or approximately 28% of our total revenues, with $861 million, or approximately 49%, generated outside the United States.
• Food and Drug Administration ("FDA"), and the Company is assessing the future commercial launch of this product. • Established Brands : We have a portfolio of established brands, which includes brands in cardiovascular, respiratory, dermatology and non-opioid pain management, including Emgality ® 2 (galcanezumab-gnlm) and Vtama ® (tapinarof) cream 1%.
• In 2025, this portfolio contributed approximately $3.7 billion, or approximately 59% of our total revenues, with approximately 91%, or $3.4 billion, generated outside the United States.
• As of December 31, 2025, we had over 10,000 employees worldwide with approximately 1,500 (15%) employees in the United States, including Puerto Rico.

Partnerships

• Bacterial Vaginosis ("BV") Xaciato® (clindamycin phosphate) vaginal gel is an FDA-approved medication for the treatment of BV in females 12 years of age and older, which is licensed through an agreement with Daré Biosciences.
• On July 27, 2022, we entered into a research collaboration and exclusive license agreement with Cirqle Biomedical ("Cirqle") that entitled us to exclusive worldwide rights to develop and commercialize the product.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:29 UTC. This page is informational and not investment advice.